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Prolonged transgene expression in glomeruli using an EBV the development of molecular technology could promote
replicon vector system combined with HVJ liposomes. practical approaches to gene therapy. Recently, gene
Background. Various gene transfer vectors as well as deliv- therapy has been used to combat acquired diseases, inery systems have been developed; however, many problems
addition to the possibility of correcting inherited geneticremain to be solved. We already achieved a technique to intro-
disorders. In the field of nephrology, basic study of geneduce genes into glomerular mesangial cells by hemagglutinating
virus of Japan (HVJ) liposome-mediated gene transfer via re- transfer into the kidney in vivo has begun [1]. The glo-
nal artery. The main limitation of this method is the transient merulus is a central region of the inflammatory response
transgene expression. in the initiation and progression of various glomerularMethod. For long-term gene expression in glomeruli, Ep-
diseases. A successful gene transfer technique targetingstein-Barr virus (EBV) replicon-based plasmid was employed,
glomeruli could provide a powerful and attractive toolcontaining the latent viral DNA replication origin (oriP) and
EBV nuclear antigen-1 (EBNA-1), which are the minimum for revealing the mechanism of glomerular diseases, and
EBV component of transgene-nuclear retention. To examine may be applicable for therapeutic intervention in dis-
the effect of EBV replicon apparatus on the duration of trans- eases. For this purpose, several approaches have been
gene expression in glomeruli in vivo, the EBV replicon vector
examined; however, neither conventional liposomes norpEBActLuc, and the control plasmid vector pActLuc were
viral vectors are useful for transferring genes into glo-adopted. These plasmid vectors were transferred into the kid-
ney via renal artery by using artificial viral envelope (AVE)- meruli [1, 2]. Therefore, several modified approaches
type HVJ liposome method, and glomerular luciferase activi- have been developed recently.
ties were analyzed at various time points after transfection. Extensive work concerning ex vivo gene transfer using
Results. On day 4, pEBActLuc and pActLuc transfer resulted
the mesangial cell vector system has been done by Kita-in equal glomerular luciferase activity, and the luciferase gene
mura et al [3]. Established mesangial cells continuouslyexpression was sustained for at least 56 days in glomeruli trans-
expressing the transfected foreign gene were injectedfected with pEBActLuc, whereas it was reduced on seven days
in glomeruli transfected with pActLuc. into the renal artery and trapped in the capillaries of the
Conclusion. The combination of EBV replicon apparatus and glomeruli. Thereafter, the expression of the exogenous
HVJ liposomes appears to be a powerful tool for long-term gene gene was observed in the glomeruli for four weeks. Thisexpression in vivo, and furthermore, it may be a promising new
mesangial cell vector system provides a strong and long-therapeutic method for the progression of renal disease.
term expression of the transfected genes in vivo. How-
ever, the transplanted mesangial cells did not migrate
into the original mesangial area, but remained in theGene therapy is a novel form of molecular medicine
endocapillary lumen. Generally, in ex vivo gene transferthat will have an impact on the theoretical treatment
approaches, rejection of implanted cells is a crucial issue,of many serious diseases. Recent advancement in the
and unfavorable functional and structural alteration ofanalysis of molecular mechanism of human diseases and
the glomerulus by transfected vector cells is inevitable.
Tryggavason et al demonstrated a successful gene
transfer into the glomerulus by means of an adenoviralKey words: gene therapy, transfection, luciferase, EBNA-1, progres-
sive renal disease. vector [4]. They tried to introduce the adenoviral vector
by means of the kidney perfusion system. The perfusionReceived for publication December 22, 1999
of the adenovirus was performed for 2 to 12 hours. Fourand in revised form October 17, 2000
Accepted for publication November 1, 2000 days later, transgene expression was observed in 75%
of the glomeruli, and the expression lasted for a fewÓ 2001 by the International Society of Nephrology
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weeks. The expression of the b-galactosidase was ob- GGG-39) was purchased from Bex (Tokyo, Japan). The
served mainly in epithelial cells, but weak in endothelial ODN were deprotected on the column, dried, resus-
cells and mesangial cells. Interestingly, they did not ob- pended in balanced salt solution (BSS; 140 mmol/L NaCl,
serve the transgene expression in parietal epithelial cells 5.4 mmol/L KCl, 10 mmol/L Tris-HCl, pH 7.6) and quan-
and tubular cells. The adenoviral perfusion system allows titated by spectrophotometer.
selective gene transfer targeting the glomerulus with high
Plasmid DNAefficiency. However, it is noteworthy that a single injec-
tion with adenovirus into the renal artery is insufficient The CLaI-NarI fragment of p205 [10] (a kind gift from
for in vivo transduction into glomerular cells. Dr. Sugden, University of Wisconsin, Madison,WI, USA),
We have reported that the hemagglutinating virus of which contains the oriP and triplet repeat (717 bp)-
Japan (HVJ) liposome-mediated gene transfer method deleted EBNA-1 sequences, was isolated, and pEBc vec-
allows selective gene delivery into the glomeruli, mainly tor was constructed by cloning this fragment into the
mesangial cells [5, 6]. This is a modified liposomal gene BglII site of pcDNA3 (Invitrogen, San Diego, CA, USA)
delivery system using HVJ envelope fusion proteins and by blunt-end ligation. It has already been reported that
DNA-binding nonhistone chromosomal proteins [high this truncated EBNA-1 provides the most efficient repli-
mobility group-1 (HMG-1)], which enhance the intro-
cation of oriP-containing DNA [10]. Then, pEBAct wasduction of DNA directly into the target cell by cell fusion
constructed by replacing the cytomegalovirus (CMV)and the translocation into the nuclei, respectively [7, 8].
promotor of pEBc with the chicken b-actin promotorFluorescein isothiocyanate (FITC)-labeled oligodeoxy-
derived from pAct-CAT [11]. Luciferase gene was iso-nucleotides (ODNs) were observed in almost all the glo-
lated from pGL2 promotor vector (Promega, Madison,meruli within 20 minutes after transfection by HVJ lipo-
WI, USA), and pEBActLuc and pActLuc were con-some-mediated gene transfer via renal artery [6]. Of
structed by cloning the luciferase gene at the HindIII andnote, immunofluorescene staining with the OX-7 anti-
BamHI sites of pEBAct and pAct-CAT, respectively.body confirmed that the FITC-positive nuclei were pres-
pEBActLacZ was constructed by inserting the b-galac-ent in the mesangial area [6]. However, the mechanism
tosidase cDNA from pSV-b-Gal (Promega) at HindIIIof the selective delivery to mesangial cells is not well
and BamHI sites of pEBAct.understood. The critical major issue of HVJ liposome
gene transfer is the short duration of gene expression.
Preparation of HVJ liposomeThe glomerular transgene expression peaks a few days
Fluorescein isothiocyanate-labeled ODN or plasmidafter transfection and declines within a few weeks.
The main reason for transient gene expression by the DNA were transfected to rat kidneys by the artificial vi-
HVJ liposome method appears to be the instability of ral envelope (AVE)-type HVJ liposome-mediated gene
the transgene in the nucleus of the transfected cells. The transfer method [12], which showed a transduction effi-
transferred gene is considered to exist extrachromo- ciency up to 10 times higher in vivo than the conventional
sommally without integration into the host genome and phosphatidylserine (PS)-type HVJ liposome method [5, 6].
that the episomal form of the transgene degrades a few The AVE-type HVJ liposome method was prepared as de-
weeks later. To achieve sustained gene expression, there scribed previously [12] with minor modifications. Briefly,
are two distinct approaches. One is the integration of a egg yolk phosphatidylcholine (ePC; Sigma, Tokyo, Japan),
transgene into the host genome; however, insertion dioleoylphosphatidylethanolamine (DOPE; NOF Corpo-
into the genome of nondividing cells has been unattain- ration, Tsukuba, Japan), egg yolk sphingomyelin (eSph;
able. Another approach is the stable retention of an Sigma), bovine brain PS (bPS; Avanti Polar Lipid Inc.,
episomal piece of DNA. Epstein-Barr virus (EBV) has Alabaster, AL, USA), and cholesterol (Sigma) were
been analyzed thoroughly in terms of its latent infection, mixed 16.7:16.7:16.7:10:50 in a molar ratio and dissolved
which is characterized by autonomous replication and in chloroform at a concentration of 30 mmol/L. The lipid
nuclear retention of EBV genome in host cells [9], and mixture (500 mL; 15 mmol) was transferred to a glass
the cis-acting oriP (the latent viral DNA origin) se-
tube and dried as a thin lipid film by evaporation. Driedquence and the trans-acting EBV nuclear antigen-1
lipid was hydrated in 200 mL of BSS containing 50 mg(EBNA-1) are required for EBV latent infection. Here,
of ODN or 200 mg of plasmid DNA, vortexed vigorously,we report the prolonged glomerular transgene expres-
and sonicated to form liposomes. The liposomes weresion by using the EBV replicon vector combined with
incubated with purified HVJ inactivated by ultravioletHVJ liposome method.
irradiation (110 erg/mm2/sec) for three minutes just be-
fore use. The liposome suspensions (containing 10 mg of
METHODS lipids) were mixed with HVJ (30,000 hemagglutinating
Fluorescein isothiocyanate-labeled ODN units) in a total volume of 2 mL of BSS. The mixture was
incubated at 48C for 10 minutes and gently shaken forThe 15-base-long phosphorothioate ODN labeled
with FITC at the 59 end (59-FITC-CGAGGGCGGCAT 60 minutes at 378C. Free HVJ was removed from the
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HVJ liposomes by discontinuous density gradient centrifu- sity, Nagoya, Japan). Cryostat sections (4 mm slice) were
incubated with OX-7, followed by rhodamine-conjugatedgation with sucrose. The HVJ liposome suspensions con-
taining approximately 5 mg of ODN or 20 mg of plasmid anti-mouse IgG (Chemicon International Inc., Temecula,
CA, USA). Thus, transfected FITC-labeled ODN andDNA in 1000 mL of BSS were maintained at 48C.
mesangial area were observed as green and red fluores-
Animals and in vivo transfection via renal artery cence, respectively. The green fluorescence of FITC and
the red fluorescence of rhodamine were taken by photo-To test the possibility of delivering a foreign gene into
mesangial cells, we selectively infused the AVE-type micrograph on the same film by double exposure.
HVJ liposome solution, including 5 mg of FITC-labeled
X-gal stainingODN into the left renal artery of 6-week-old male Sprague-
Dawley (SD) rats (Japan SLC, Inc., Hamamatsu, Japan) The pEBActLacZ-transfected rats (N 5 4) were anes-
thetized by intraperitoneal injection of pentobarbital andweighing approximately 150 g. Six rats were anesthetized
by intraperitoneal injection of pentobarbital (50 mg/kg) sacrificed four days after transfection. The glomeruli
from transfected left kidneys or contralateral right kid-and handled in a humane fashion in accordance with the
guidelines of the Animal Committee of Osaka Univer- neys were isolated with the sieving technique and im-
mersed in the 1% glutaraldehyde in phosphate-bufferedsity. The left kidney and renal artery were surgically
exposed with a mid line incision, and a 24 G-gauge cathe- saline (PBS) for one hour. The X-gal assay was per-
formed as follows [13]. Glomeruli were washed by PBSter (Terumo, Tokyo, Japan) was inserted into the left
renal artery. After clamping the proximal site of the and then incubated at 378C for four hours in X-gal solu-
tion [PBS: 1 mg/mL X-gal, 5 mmol/L K3Fe(CN)6, 5 mmol/Labdominal aorta, the left kidney was perfused with saline
via renal artery. Then, HVJ liposome solution (1 mL) K4Fe(CN)6, 2 mmol/L MgCl2]. To stop the enzymatic reac-
tion, the sections were washed in water.was injected into the left kidney via the left renal artery
with a one shot method. The HVJ liposome solution was
Luciferase assayincubated for 10 minutes. After incubation, the catheter
was removed, and the puncture was fixed with Aronalfa Glomerular luciferase activity was measured as re-
ported by Wolff et al [14] with minor modification. At(Toagosei Co. Ltd., Tokyo, Japan). Thereafter, the ar-
tery clamp was released. FITC-labeled ODN-transfected various points after transfection, three to six rats were
examined for glomerular luciferase activity. Transfectedkidneys were removed 10 minutes after transfection, and
four sections (4 mm thick) of unfixed snap-frozen speci- left kidney was removed, and glomeruli were isolated
by graded sieving technique. Isolated glomeruli from amens from each transfected kidney were examined by
fluorescence microscopy. pEBActLuc or pAct-Luc gene transfected kidney were
homogenized in 50 mL of 1 3 cell lysis reagent (Promega)To examine the efficiency of transgene expression in
glomeruli, AVE-type HVJ liposome solution, including and centrifuged. The supernatant of the lysate was exam-
ined for luciferase activity using Promega Luciferase20 mg of the pEBActLacZ gene, was transferred as de-
scribed previously in this article. The pEBActLacZ gene Assay System and a Lumat LB 9501 luminophotometer
(EG&G Berthold, Wildbad, Germany). Glomerular lu-transfected rats (N 5 4) were sacrificed four days after
transfection, and b-galactosidase expression was exam- ciferase activity of transfected kidney was corrected on
the basis of glomerular protein concentration, which wasined by X-gal staining.
To quantitate the transgene expression in glomeruli, determined by the Bio-Rad protein assay system (Bio-
Rad, Hercules, CA, USA) [15]. The data were expressedAVE-type HVJ liposome solution, including 20 mg of
either pEBActLuc gene or pActLuc gene, was intro- by dividing the corrected luciferase activity (luciferase/
protein concentration) in glomeruli for each individualduced into left kidney by the AVE-type HVJ liposome
method. The pEBActLuc transfected rats were sacrificed transfected rat. We repeated the experiments at least
three times.4, 7, 14, 21, 28, 42, 56, 70, and 84 days after transfection.
The pActLuc transfected rats were sacrificed 4, 7, 14, 21,
Polymerase chain reaction analysisand 28 days after transfection. The glomerular lucifer-
ase activities from rats transfected with pEBActLuc or The question of whether the transfected EBV replicon
vector can exist in the glomerulus was examined one,pActLuc were analyzed.
four, and eight weeks after transfection using polymerase
Immunofluorescence chain reaction (PCR) analysis on isolated glomeruli. Glo-
merular DNA extracted from pEBActLuc-transfectedTo identify the cells where FITC-labeled ODN were
introduced, the FITC-labeled ODN transfected kidneys animals was subjected to PCR analysis using two primers
specific for the pEBActLuc plasmid vector, TCGCCT(N 5 6) were stained with the monoclonal antibody
OX-7, a specific marker for mesangial (a kind gift from Dr. TCTATCGCCTTCTT and TTTCGCCACCTCTGAC
TTGA, which yield 827 bp fragments. The cycles wereKen-ichi Isobe and Dr. Seichi Matsuo, Nagoya Univer-
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Fig. 1. Representative fluorescence photo-
micrographs of FITC-labeled oligodeoxynu-
cleotide (ODN)-transfected kidneys and glo-
merular localization of FITC-labeled ODN.
(A) FITC-labeled ODNs were observed in all
glomeruli (magnification 3100). (B) FITC-
labeled phosphorothioate ODN accumulated
in the nuclei of glomerular cells (magnification
3400). (C ) To examine the cellular localiza-
tion of the transfected ODN, OX-7, a specific
monoclonal antibody for mesangial cells, and
rhodamine-conjugated rabbit anti-mouse IgG
were used to stain mesangial cells. FITC
(green)-positive nuclei were seen mainly in
the mesangial area (red). The color of FITC
positive nuclei thus changed from green to
yellow (magnification 3400).
Fig. 2. b-Galactosidase expression in glomer-
uli. Hemagglutinating virus of Japan (HVJ)
liposomes containing the pEBActLacZ gene
were introduced into the left kidney via left
renal artery. The X-gal staining was per-
formed on isolated glomeruli four days after
pEBActLacZ gene transfection. (A) b-Galac-
tosidase expression was observed in 70% of
glomeruli from pEBActLacZ transfected left
kidneys. (B) No staining was observed in the
glomeruli from contralateral right kidneys.
948C for 30 seconds, 588C for 1 minute, and 728C for 1 fer method permitted an effective introduction of the
gene into mesangial cells.minute. After 35 cycles, the PCR product was analyzed
as well as the pEBActLuc plasmid vectors as a positive
Gene expression in glomerulicontrol.
To examine the transgene expression by this gene
transfer method, the X-gal staining was performed on
RESULTS isolated glomeruli four days after pEBActLacZ gene
Gene transfer into mesangial cells transfection. Four days after transfection, b-galactosi-
dase expression was observed in 70% of glomeruli fromTo determine the possibility of introducing a foreign
pEBActLacZ-transfected left kidneys (Fig. 2A). Nogene into glomeruli, we selectively transferred FITC-
X-gal–positive glomeruli were observed in those fromlabeled ODN into the kidneys of normal rats via renal
contralateral right kidneys (Fig. 2B).artery by the AVE-type HVJ liposome method, and the
luminescence of transfected kidneys was examined 10
Prolonged transgene expression in glomeruli byminutes after transfection. FITC-labeled ODN were ob-
the EBV replicon vector system.served in all glomeruli (Fig. 1A) and accumulated in the
nuclei of the glomeruli (Fig. 1B). No luminescence was To analyze the time course of the glomerular transgene
expression, AVE-type HVJ liposome trapping pEBActLucobserved in tubular epithelial cells. Immunofluorescence
staining with the OX-7 antibody confirmed that the or pActLuc was injected into left kidney via renal artery,
and glomeruli were isolated at various time points afterFITC-positive nuclei were present in the mesangial area
(red staining in Figure 1C). These observations indicate transfection. On day 4, pEBActLuc and pActLuc trans-
fection resulted in almost equal glomerular luciferasethat the AVE-type HVJ liposome-mediated gene trans-
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DNA one, four, and eight weeks after pEBActLuc trans-
fection. PCR analysis demonstrated that the EBV repli-
con vector existed in transfected glomeruli even eight
weeks after transfection (Fig. 3B).
DISCUSSION
This report describes a method to prolong the trans-
gene expression in glomeruli by a nonviral method. Non-
viral gene delivery techniques have resulted in a limited
time span of transgene expression to date [1]. A number
of reasons may explain this phenomenon, including epi-
somal form of the transgene, DNA degradation or modi-
fication, and promoter silencing. The main reason ap-
pears to be the instability of the transgene in the nucleus
of the transfected cells. Other direct gene delivery sys-
tems targeting glomeruli also have shown transient gene
expression. The adenoviral perfused delivery system was
successful within a few weeks [4]; the longer expression
times, up to four weeks, were observed with ex vivo
approaches [16]. Here, we observed sustained glomeru-
lar luciferase activity 56 days after pEBActLuc gene
transfection. Considering the short half-life of luciferase
protein, this value is due to the protein synthesized within
Fig. 3. Luciferase activity in glomeruli. (A) Luciferase activities in glo- a few hours before sacrificing the animal. It is difficult
meruli transfected with pEBActLuc [EB(1); d] or pActLuc [EB(2); to compare our data directly with theirs; however, our
s] were analyzed on days 4, 7, 14, 21, 28, 42, 56, 70, and 84. The
present work shows a longer gene expression than thedata were expressed by dividing corrected luciferase activity (luciferase
activity/protein concentration) in glomeruli for each individual trans- viral-mediated gene transfer system, and sustained gene
fected rat at various time points after transfection. (B) PCR analysis expression was observed in glomeruli at least eight weeks
demonstrated that amplified products for EBV replicon vector (827 bp)
after transfection.were detected in glomeruli 1 week (lane 1), 4 weeks (lane 2), and 8
weeks (lane 3) after pEBActLuc gene transfection. EBV replicon vector Epstein-Barr virus has been known to induce latent
plasmid pEBActLuc (lane 4) was amplified as positive control. No infection in human B lymphocytes. Numerous in vitroamplified products were detected by omitting pEBActLuc vector (lane
studies have demonstrated that these features are medi-5). M is molecular weight marker.
ated by the origin of latent viral DNA replication (oriP)
and a latent viral protein, EBNA-1 [9]. Therefore, we
activity (11.8 6 0.2 3 104 vs. 7.1 6 0.4 3 104 RLU/mg constructed an EBV replicon vector by cloning the
glomerular protein, respectively). When pActLuc ex- EBNA-1 and oriP sequences in the same plasmid and
pression vector (without EBV replicon sequence) was examined the effect of EBV replicon apparatus on the
introduced, glomerular luciferase expression gradually duration of transgene expression.
decreased. The glomerular luciferase activity seven days
There are several advantages of EBV replicon vectors.after transfection with pActLuc was one order of magni-
One is the nuclear retention of the transgene [9]. Wetude lower (9.7 6 0.2 3 103 RLU/mg glomerular protein)
showed the persistent retention of pEBActLuc plasmidand decreased to two orders of magnitude lower levels
vector in glomeruli at least eight weeks after transfectionby 28 days (7.3 6 0.2 3 102 RLU/mg glomerular protein).
by PCR analysis. In accordance with these observations,In contrast, with pEBActLuc, luciferase gene expression
we demonstrated the prolonged luciferase expression inlevel remained constant 56 days after transfection (5.3 6
glomeruli. Nuclear retention appears to be mediated by0.2 3 104 RLU/mg glomerular protein) and detected 70
the association of the oriP sequence with the nucleardays after transfection, although the expression level was
matrix [17]. The 65 bp dyad symmetry (DS) region coulddecreased (2.2 6 0.4 3 103 RLU/mg glomerular protein).
bind EBNA-1, although the binding is not as tight asOn 84 days after transfection, the luciferase activity was
with the FR region [18]. DS is required for maintainingdecreased to two orders of magnitude lower levels (5.2 6
EBV genome in an extrachromosomal state [19]. Dele-0.9 3 102 RLU/mg glomerular protein; Fig. 3A).
tion analysis of EBNA-1 binding sites abolishes the ca-
DNA retention in glomeruli pacity for extrachromosomal maintenance. This also im-
plies that the interaction of EBNA-1 with the oriPTo address whether transfected EBV replicon vector
can exist in the glomerulus, we analyzed glomerular sequence is necessary for episomal retention of EBV
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genome. Recently, Saeki et al demonstrated that the the most efficient in vivo gene transfer system targeting
plasmid containing the EBV sequence was retained ex- glomerular mesangial cells. For in vivo gene transfer,
trachromosomally in the nucleus of cultured rodent cells, AVE-type HVJ liposome-mediated gene transfer method,
BHK-21, while the plasmid with no EBV sequence was which has a virus-mimicking lipid composition similar
lost between days 3 and 9 after transfection [20]. Al- to the envelope of the human immunodeficiency virus,
though they indicated the long-term gene expression showed a transduction efficiency up to 10 times higher
without autonomous replication in rodent cells, they in vivo than the conventional PS-type anionic HVJ lipo-
showed that the transgene tends to be lost between days some method (ePS:bPS:Chol 5 5:1:4 molar ratio). The
9 and 14 in dividing cultured rodent cells. However, they strong net negative charge of the anionic HVJ liposome
suggested that the EBV replicon vector might be more seems to decrease the association with plasma mem-
stable in nondividing rodent cells compared with dividing branes of cultured cells in vitro, but could facilitate effec-
rodent cells, presumably because of the ability of the tive transfection in vivo by escaping from negatively
nuclear retention. With this point of view, glomerular charged macromolecules around the cells. FITC-labeled
mesangial cells seem to be a good target for long-term ODNs were observed in all glomeruli and observed in
gene expression by EBV replicon vector. 60 to 70% of nuclei in mesangial area. These results
The activation of viral gene transcription by EBNA-1 suggest that the AVE-type HVJ liposome-mediated
is the second advantage of the EBV replicon vector. The gene transfer method enabled an introduction of the
binding of EBNA-1 to the oriP sequence has been indi- gene effectively into mesangial cells. The AVE-type HVJ
cated, and among the three-clustered loci of the oriP re- liposome may increase the introduced plasmid vector
gions, a 30-bp family of repeats (FR) region of oriP binds copies compared with the conventional HVJ liposome
EBNA-1 most tightly [18]. When this FR region is inserted method. However, the lipid composition of liposome
into the plasmid containing a chloramphenicol acetyl- has little effect on the duration of transgene expression.
transferase (CAT) gene, CAT gene expression is en- Therefore, EBV replicon vector can be applicable to
hanced in EBNA-1–positive cells, but not in EBNA-1– other gene transfer methods in addition to the HVJ lipo-
negative cells [18, 21, 22]. This indicates that EBNA-1 some method.
acts as the transcriptional enhancer at the oriP region One problem of the EBV replicon vector is the onco-
[23]. On day 4, glomerular luciferase activity by pEBAc- genecity of EBNA-1 protein. Indeed, transgenic mouse
tluc was same as that by pActLuc. However, the number harboring EBNA-1 gene driven by a B-lymphocyte-spe-
of transfected pEBActLuc copies appeared to be half of cific enhancer generated lymphoma. However, several
the number of transfected pActLuc copies, because the reports indicate that EBV proteins except EBNA-1 are
molecular size of pEBActLuc is twice as large as that
essential for B-lymphocyte transformation [28–32]. We
of pActLuc. It suggests that luciferase expression by
observed that EBNA-1 stable transformants in HEK-pEBActLuc was transcriptionally enhanced and about
293 cells could not grow in soft-agar plates and weretwice as high as that by pActLuc.
sensitive to serum depletion. Gene transfer to lympho-The autonomous replication of the plasmid in primate
cytes by the HVJ liposome was extremely inefficient,and canine cells is the third advantage of EBV replicon
and no pathological changes were found in kidney trans-vector [10, 24]. As previously reported, the EBV replicon
fected with the EBV replicon vector. To exclude thevector could not replicate in rodent cells [10, 24], and the
toxicity of pEBActLuc gene transfection, we monitoredglomerular luciferase activity did not increase. However,
the release of the cytoplasmic enzyme lactate dehydroge-autonomous replication may forward the application of
nase (LDH) from cultured mesangial cells treated withgene therapy in humans.
pEBActLuc or pActLuc gene transfer. The percentageThe latent infection of EBV was also shown to be
of LDH released was defined as the ratio of LDH activitymediated by the immunotolerant mechanism that Gly-
in the supernatant of the sum of the LDH amount mea-Ala repeat domain of EBNA1 could inhibit the presenta-
sured in the cell lysate. pEBActLuc gene transfer did nottion of major histocompatibility complex (MHC) class I
significantly induce the release of LDH over pActLuc-restricted cytotoxic T-cell epitopes by inhibiting antigen
transfected mesangial cells (7.58 6 0.84 and 7.96 6processing via the ubiquitin/proteasome pathway [25, 26].
1.31%, percentage of LDH release in pActLuc and pEB-Mukherijee et al reported that murine cytotoxic T lym-
ActLuc transfected mesangial cells, respectively). There-phocytes recognized an epitope in an EBNA-1 fragment,
fore, coupling the EBV replicon vector with HVJ lipo-but failed to lyze EBNA-1–expressing mouse cells [27].
some appears to be a safe and efficient gene transferThus, prolonged high expression of a transgene in an
system to target glomerular mesangial cells.EBV replication vector in rats may be mediated by nu-
In conclusion, the EBV replicon vector system com-clear retention, transcription activation, and immuno-
bined with the AVE-type HVJ liposome method cantolerance.
To our knowledge, HVJ liposome method is one of target glomerular mesangial cells, enhance the transcrip-
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